Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Retinoblastoma Phase II Expanded Access Clinical Trial

NCT06679634 is registered in ClinicalTrials.gov with Targeted Therapy Technologies, LLC as lead sponsor.

NCT NCT06679634
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06679634 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Retinoblastoma Phase II Expanded Access Clinical Trial
Lead sponsor
Targeted Therapy Technologies, LLC
Phase
Phase 2
Overall status
Recruiting
Start date
February 21, 2025
Completion date
December 31, 2029
Enrollment
30 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

retinoblastoma